



MEN

FIRST CANCER SITE
OESOPHAGUS
OESOPHAGUS
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

ESOFAGO
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	7598		9562		9562		7598		2977		479		150		7598	9562
Person-years ▶	10533		11963		1431		4055		4511		1428		539		10533	11963
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND OESOPHAGUS	290	1.45	411	1.81	121	4.45	82	1.11	146	1.77	47	1.55	15	1.13	8.50	15.33
HEAD AND NECK	76	8.19	96	9.09	20	15.58	16	4.47	44	11.12	11	8.66	5	10.61	6.33	7.14
ORAL CAVITY	31	14.16	34	13.66	3	10.04	8	9.55	18	19.26	4	13.19	1	8.78	2.74	2.63
PHARYNX	27	13.13	36	15.42	9	32.41	7	8.88	13	14.64	4	14.26	3	30.13	2.37	2.81
LARYNX	18	3.58	26	4.53	8	11.31	1	0.51	13	6.10	3	4.37	1	3.88	1.23	1.69
OESOPHAGUS	1	0.42	1	0.37	0	0.00	1	1.11	0	0.00	0	0.00	0	0.00	-0.13	-0.14
STOMACH	12	1.00	22	1.60	10	5.56	5	1.07	5	1.04	2	1.17	0	0.00	0.00	0.69
COLON RECTUM	23	0.85	30	0.97	7	1.91	7	0.70	11	0.99	5	1.20	0	0.00	-0.39	-0.07
COLON	16	0.86	23	1.09	7	2.81	5	0.74	7	0.92	4	1.39	0	0.00	-0.24	0.16
RECTUM	7	0.82	7	0.72	0	0.00	2	0.63	4	1.14	1	0.78	0	0.00	-0.15	-0.23
LIVER	12	1.45	19	2.03	7	6.33	5	1.64	4	1.16	1	0.80	2	3.80	0.36	0.81
GALLBLADDER	3	1.46	3	1.28	0	0.00	2	2.62	1	1.21	0	0.00	0	0.00	0.09	0.06
PANCREAS	5	0.92	10	1.62	5	6.73	4	1.99	1	0.45	0	0.00	0	0.00	-0.04	0.32
LUNG	74	2.04	128	3.10	54	10.69	18	1.32	41	2.74	13	2.45	2	0.89	3.59	7.25
SKIN MELANOMA	2	0.69	2	0.62	0	0.00	0	0.00	2	1.64	0	0.00	0	0.00	-0.08	-0.10
MESOTHELIOMA	2	1.79	2	1.59	0	0.00	0	0.00	1	2.12	1	5.70	0	0.00	0.08	0.06
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.07	-0.07
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
PROSTATE	28	0.72	32	0.73	4	0.81	6	0.44	14	0.87	5	0.78	3	1.06	-1.05	-1.01
TESTIS	1	4.31	1	3.79	0	0.00	0	0.00	0	0.00	0	0.00	1	99.05	0.07	0.06
KIDNEY AND RENAL PELVIS	6	0.93	12	1.64	6	7.10	2	0.85	3	1.11	1	1.03	0	0.00	-0.04	0.39
BLADDER AND URINARY TRACT	23	1.05	23	0.92	0	0.00	9	1.10	11	1.22	2	0.61	1	0.68	0.10	-0.17
URINARY BLADDER	20	0.95	20	0.84	0	0.00	8	1.02	9	1.05	2	0.63	1	0.71	-0.09	-0.32
URINARY TRACT	3	3.09	3	2.71	0	0.00	1	2.76	2	5.07	0	0.00	0	0.00	0.19	0.16
BRAIN AND CENTRAL NERVOUS SYSTEM	3	1.27	3	1.12	0	0.00	0	0.00	2	2.02	1	2.91	0	0.00	0.06	0.03
THYROID	1	1.06	2	1.88	1	8.63	1	2.95	0	0.00	0	0.00	0	0.00	0.01	0.08
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	2	0.35	2	0.31	0	0.00	0	0.00	1	0.42	0	0.00	1	2.67	-0.36	-0.38
MYELOMA	1	0.38	1	0.34	0	0.00	1	1.03	0	0.00	0	0.00	0	0.00	-0.15	-0.16
LEUKAEMIAS	2	0.44	3	0.58	1	1.57	1	0.59	0	0.00	1	1.51	0	0.00	-0.24	-0.18
LYMPHOID LEUKAEMIAS	1	0.45	1	0.40	0	0.00	1	1.19	0	0.00	0	0.00	0	0.00	-0.11	-0.13
MYELOID LEUKAEMIAS	1	0.50	2	0.88	1	3.60	0	0.00	0	0.00	1	3.30	0	0.00	-0.09	-0.02
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	14	1.39	20	1.74	6	4.22	5	1.32	5	1.23	4	2.65	0	0.00	0.37	0.71

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
OESOPHAGUS
OESOPHAGUS
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

ESOFAGO
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	2291		2954		2954		2291		920		168		64		2291	2954
Person-years ▶	3471		3908		438		1213		1511		540		208		3471	3908
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND OESOPHAGUS	58	1.41	77	1.65	19	3.45	21	1.43	22	1.27	11	1.70	4	1.49	4.84	7.75
HEAD AND NECK	9	16.86	11	18.26	2	29.07	4	21.44	2	8.80	3	35.25	0	0.00	2.44	2.66
ORAL CAVITY	2	6.99	2	6.16	0	0.00	1	9.88	1	8.37	0	0.00	0	0.00	0.49	0.43
PHARYNX	3	25.79	4	30.62	1	69.81	1	24.98	1	19.64	1	54.27	0	0.00	0.83	0.99
LARYNX	4	30.53	5	33.93	1	61.22	2	44.08	0	0.00	2	97.13	0	0.00	1.11	1.24
OESOPHAGUS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.06	-0.06
STOMACH	2	0.79	3	1.02	1	2.48	1	1.01	1	0.97	0	0.00	0	0.00	-0.16	0.01
COLON RECTUM	10	1.55	10	1.36	0	0.00	4	1.71	2	0.75	3	2.97	1	2.32	1.02	0.68
COLON	7	1.51	7	1.32	0	0.00	3	1.78	1	0.52	2	2.74	1	3.19	0.68	0.44
RECTUM	3	1.66	3	1.46	0	0.00	1	1.52	1	1.33	1	3.57	0	0.00	0.34	0.24
LIVER	2	1.79	3	2.36	1	6.40	0	0.00	1	2.16	1	5.81	0	0.00	0.26	0.44
GALLBLADDER	1	1.12	1	0.97	0	0.00	1	2.94	0	0.00	0	0.00	0	0.00	0.03	-0.01
PANCREAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.49	-0.49
LUNG	8	3.03	16	5.37	8	23.72	2	2.20	5	4.47	1	2.34	0	0.00	1.54	3.33
SKIN MELANOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.21	-0.21
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	9	0.87	11	0.95	2	1.58	3	0.85	5	1.12	1	0.60	0	0.00	-0.37	-0.14
CERVIX UTERI	3	5.76	4	6.78	1	14.36	2	10.57	0	0.00	1	13.21	0	0.00	0.71	0.87
CORPUS UTERI	2	1.07	2	0.95	0	0.00	0	0.00	0	0.00	1	3.33	1	8.20	0.04	-0.03
OVARY	1	0.79	1	0.70	0	0.00	0	0.00	0	0.00	0	0.00	1	12.47	-0.08	-0.11
KIDNEY AND RENAL PELVIS	2	2.00	3	2.66	1	7.95	0	0.00	2	4.71	0	0.00	0	0.00	0.29	0.48
BLADDER AND URINARY TRACT	1	0.63	1	0.55	0	0.00	1	1.74	0	0.00	0	0.00	0	0.00	-0.17	-0.21
URINARY BLADDER	1	0.68	1	0.60	0	0.00	1	1.88	0	0.00	0	0.00	0	0.00	-0.14	-0.17
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.17	-0.17
THYROID	1	1.51	2	2.72	1	13.90	1	4.70	0	0.00	0	0.00	0	0.00	0.10	0.32
HODGKIN LYMPHOMA	1	10.86	1	9.59	0	0.00	0	0.00	1	25.13	0	0.00	0	0.00	0.26	0.23
NON-HODGKIN LYMPHOMA	2	1.30	2	1.15	0	0.00	0	0.00	1	1.52	0	0.00	1	9.69	0.13	0.07
MYELOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.21	-0.21
LEUKAEMIAS	3	2.94	4	3.42	1	6.82	2	5.27	1	2.37	0	0.00	0	0.00	0.57	0.72
LYMPHOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.13	-0.13
MYELOID LEUKAEMIAS	3	6.25	4	7.31	1	15.00	2	11.49	1	5.03	0	0.00	0	0.00	0.73	0.88
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.03
OTHER AND ILL DEFINED SITES	1	0.33	2	0.57	1	2.20	0	0.00	1	0.81	0	0.00	0	0.00	-0.59	-0.38

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio